Molecular testing for treatment of metastatic non-small cell lung cancer

How to implement evidence-based recommendations

Benjamin Levy, Marc D. Chioda, Dana Herndon, John W. Longshore, Mohamed Mohamed, Sai Hong Ignatius Ou, Craig Reynolds, Jaspal Singh, Ignacio I. Wistuba, Paul A. Bunn, Fred R. Hirsch

Research output: Contribution to journalArticle

Abstract

The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians’ lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.

Original languageEnglish (US)
Pages (from-to)1175-1181
Number of pages7
JournalOncologist
Volume20
Issue number10
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Practice Guidelines
Protein-Tyrosine Kinases
Patient Selection
Lung Neoplasms
Neoplasms
Therapeutics
Guidelines
Physicians
Oncologists

Keywords

  • Biological markers
  • Carcinoma
  • Molecular diagnostic testing
  • Molecular targeted therapy
  • Non-small cell lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Levy, B., Chioda, M. D., Herndon, D., Longshore, J. W., Mohamed, M., Ou, S. H. I., ... Hirsch, F. R. (2015). Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations. Oncologist, 20(10), 1175-1181. https://doi.org/10.1634/theoncologist.2015-0114

Molecular testing for treatment of metastatic non-small cell lung cancer : How to implement evidence-based recommendations. / Levy, Benjamin; Chioda, Marc D.; Herndon, Dana; Longshore, John W.; Mohamed, Mohamed; Ou, Sai Hong Ignatius; Reynolds, Craig; Singh, Jaspal; Wistuba, Ignacio I.; Bunn, Paul A.; Hirsch, Fred R.

In: Oncologist, Vol. 20, No. 10, 01.09.2015, p. 1175-1181.

Research output: Contribution to journalArticle

Levy, B, Chioda, MD, Herndon, D, Longshore, JW, Mohamed, M, Ou, SHI, Reynolds, C, Singh, J, Wistuba, II, Bunn, PA & Hirsch, FR 2015, 'Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations', Oncologist, vol. 20, no. 10, pp. 1175-1181. https://doi.org/10.1634/theoncologist.2015-0114
Levy, Benjamin ; Chioda, Marc D. ; Herndon, Dana ; Longshore, John W. ; Mohamed, Mohamed ; Ou, Sai Hong Ignatius ; Reynolds, Craig ; Singh, Jaspal ; Wistuba, Ignacio I. ; Bunn, Paul A. ; Hirsch, Fred R. / Molecular testing for treatment of metastatic non-small cell lung cancer : How to implement evidence-based recommendations. In: Oncologist. 2015 ; Vol. 20, No. 10. pp. 1175-1181.
@article{58f5e3f84c4a4f49838156a885359ede,
title = "Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations",
abstract = "The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians’ lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.",
keywords = "Biological markers, Carcinoma, Molecular diagnostic testing, Molecular targeted therapy, Non-small cell lung",
author = "Benjamin Levy and Chioda, {Marc D.} and Dana Herndon and Longshore, {John W.} and Mohamed Mohamed and Ou, {Sai Hong Ignatius} and Craig Reynolds and Jaspal Singh and Wistuba, {Ignacio I.} and Bunn, {Paul A.} and Hirsch, {Fred R.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1634/theoncologist.2015-0114",
language = "English (US)",
volume = "20",
pages = "1175--1181",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Molecular testing for treatment of metastatic non-small cell lung cancer

T2 - How to implement evidence-based recommendations

AU - Levy, Benjamin

AU - Chioda, Marc D.

AU - Herndon, Dana

AU - Longshore, John W.

AU - Mohamed, Mohamed

AU - Ou, Sai Hong Ignatius

AU - Reynolds, Craig

AU - Singh, Jaspal

AU - Wistuba, Ignacio I.

AU - Bunn, Paul A.

AU - Hirsch, Fred R.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians’ lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.

AB - The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians’ lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.

KW - Biological markers

KW - Carcinoma

KW - Molecular diagnostic testing

KW - Molecular targeted therapy

KW - Non-small cell lung

UR - http://www.scopus.com/inward/record.url?scp=84943244506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943244506&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0114

DO - 10.1634/theoncologist.2015-0114

M3 - Article

VL - 20

SP - 1175

EP - 1181

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -